Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Abstract 2507: Bivalent adenylate cyclase (CYA)-based therapeutic vaccines: eradication of tumor cells expressing different antigens over time

Michaël Esquerré, Marie Momot, Anne Goubier, Yolande Misseri, Marie-Christine Bissery

Cancer Res (2015) 75 (15_Supplement): 2507.

https://doi.org/10.1158/1538-7445.AM2015-2507

Published: 01 August 2015

View article titled, Abstract 2507: Bivalent adenylate cyclase (CYA)-based therapeutic vaccines: eradication of tumor cells expressing different antigens over time

Journal Articles

Abstract 714: Non-invasive monitoring of the antitumor activity of SAR650984 anti-CD38 antibody against disseminated human Daudi lymphoma using ¹⁸F-FDG micro Positron Emission Tomography

Laurent D.D. Besret, Sébastien D'Heilly, Alain Selingue, Pascale Lejeune, Patricia Vrignaud, Marie-Christine Bissery, Chantal Carrez

Cancer Res (2010) 70 (8_Supplement): 714.

https://doi.org/10.1158/1538-7445.AM10-714

Published: 15 April 2010

View article titled, Abstract 714: Non-invasive monitoring of the antitumor activity of SAR650984 anti-CD38 antibody against disseminated human Daudi lymphoma using 18F-FDG micro Positron Emission Tomography

Journal Articles

Abstract #2797: In vivo therapeutic synergy of SAR650984, a humanized anti-CD38 antibody, in combination with melphalan in a multiple myeloma xenograft.

Pascale Lejeune, Véronique Blanc, Jacqueline Courta, Coumaran Egile, Patricia Vrignaud, Jutta Deckert, Peter Park, Marie-Christine Bissery

Cancer Res (2009) 69 (9_Supplement): 2797.

Published: 01 May 2009

View article titled, Abstract #2797: In vivo therapeutic synergy of SAR650984, a humanized anti-CD38 antibody, in combination with melphalan in a multiple myeloma xenograft.

Journal Articles

Abstract #859: Broad spectrum of antitumor activity of SAR650984, a humanized anti-CD38 antibody targeting hematological malignancies

Pascale Lejeune, Jutta Deckert, Michele Mayo, Kathy Whiteman, Starrla Johnson, Cheryl Guyre, Véronique Blanc, Peter Park, Robert Lutz, Marie-Christine Bissery, Patricia Vrignaud

Cancer Res (2009) 69 (9_Supplement): 859.

Published: 01 May 2009

View article titled, Abstract #859: Broad spectrum of antitumor activity of SAR650984, a humanized anti-CD38 antibody targeting hematological malignancies

Journal Articles

Broad spectrum of antitumor activity of aflibercept (VEGF Trap) in tumor-bearing mice.

Marielle Chiron, Pascale Lejeune, Friedhelm Bladt, Patricia Vrignaud, Marie-Christine Bissery.

Cancer Res (2008) 68 (9_Supplement): 380.

Published: 01 May 2008

View article titled, Broad spectrum of antitumor activity of aflibercept (VEGF Trap) in tumor-bearing mice.

Journal Articles

Combination of the antiangiogenic agent aflibercept (VEGF Trap) with docetaxel or gemcitabine results in greater antitumor activity in tumor bearing mice.

Pascale Lejeune, Marielle Chiron, Ronan Le Moigne, Patricia Vrignaud, Marie-Christine Bissery

Cancer Res (2008) 68 (9_Supplement): 1107.

Published: 01 May 2008

View article titled, Combination of the antiangiogenic agent aflibercept (VEGF Trap) with docetaxel or gemcitabine results in greater antitumor activity in tumor bearing mice.

Journal Articles

Antitumor activity of alvocidib (flavopiridol) in mice bearing human hematological tumors

Claudia Zuany-Amorim, Cecile Combeau, Teresa Granda, Patricia Vrignaud, Marie-Christine Bissery

Cancer Res (2008) 68 (9_Supplement): 752.

Published: 01 May 2008

View article titled, Antitumor activity of alvocidib (flavopiridol) in mice bearing human hematological tumors

Journal Articles

Characterization of vascular-disrupting properties of the Combretastatin A4 derivative AVE8062 in the rat aortic ring assay

Marielle Chiron, Joyce Muller, Nicole Diallo, Coumaran Egile, Brigitte Demers, Patricia Vrignaud, Marie-Christine Bissery

Cancer Res (2008) 68 (9_Supplement): 1443.

Published: 01 May 2008

View article titled, Characterization of vascular-disrupting properties of the Combretastatin A4 derivative AVE8062 in the rat aortic ring assay

Journal Articles

Demonstration in animal and human of AVE8062-induced tumor blood flow shutdown using dynamic contrast enhanced-ultrasonography (DCE-US).

Erwan Jouannot, Chantal Carrez, Nathalie Lassau, Pascale Lejeune, Brigitte Demers, Patricia Vrignaud, Marie-Christine Bissery

Cancer Res (2007) 67 (9_Supplement): LB-328.

Published: 01 May 2007

View article titled, Demonstration in animal and human of AVE8062-induced tumor blood flow shutdown using dynamic contrast enhanced-ultrasonography (DCE-US).

Journal Articles

In vivo pre-clinical evaluation of the IGF-1R-specific antibody AVE1642 as single agent and in combination with Velcade ^® /Bortezomib

Friedhelm Bladt, Patricia Vrignaud, Stephane Guerif, Noelle Boussac, Thomas Chittenden, Thierry Hercend, Marielle Chiron, Marie-Christine Bissery

Cancer Res (2007) 67 (9_Supplement): 4115.

Published: 01 May 2007

View article titled, In vivo pre-clinical evaluation of the IGF-1R-specific antibody AVE1642 as single agent and in combination with Velcade ® /Bortezomib

Journal Articles

In vivo synergy between trastuzumab (herceptin ^® ) and larotaxel (RPR 109881A), a new taxoid.

Patricia Vrignaud, Marielle Chiron, Murray Stackhouse, Claudia Zuany-Amorim, Helene Goulaouic, Marie-Christine Bissery

Cancer Res (2007) 67 (9_Supplement): 1432.

Published: 01 May 2007

View article titled, In vivo synergy between trastuzumab (herceptin ® ) and larotaxel (RPR 109881A), a new taxoid.

Journal Articles

Early evaluation of the antimitotic and vascular targeting agent AVE8062A in melanoma tumor bearing mice using dynamic contrast enhanced-ultrasonography (DCE-US)

Sonia Lavisse, Pascale Lejeune, Marie-Christine Bissery, Nicolas Elie, Valerie Rouffiac, Aude Brule, Estelle Bribes, Brigitte Demers, Patricia Vrignaud, Thierry Hercend, Pierre Peronneau, Nathalie Lassau

Cancer Res (2006) 66 (8_Supplement): 233.

Published: 15 April 2006

View article titled, Early evaluation of the antimitotic and vascular targeting agent AVE8062A in melanoma tumor bearing mice using dynamic contrast enhanced-ultrasonography (DCE-US)

Journal Articles

Preclinical evaluation of SAR3419 (huB4-DM4), an anti-CD19-maytansinoid immunoconjugate, for the treatment of B cell lymphomas

Robert J. Lutz, Claudia Zuany-Amorim, Patricia Vrignaud, Michele F. Mayo, Stephane Guerif, Hongsheng Xie, Véronique Blanc, Marie-Christine Bissery, Thierry Hercend

Cancer Res (2006) 66 (8_Supplement): 877–878.

Published: 15 April 2006

View article titled, Preclinical evaluation of SAR3419 (huB4-DM4), an anti-CD19-maytansinoid immunoconjugate, for the treatment of B cell lymphomas

Journal Articles

In vitro and in vivo effects of the combination of SR57746A (Xaliproden), a neuroprotective agent, with oxaliplatin (ELOXATIN®) in colon tumors

Patricia Vrignaud, Teresa G. Granda, Bernard Bourrié, Pierre Casellas, Marie-Christine Bissery

Cancer Res (2006) 66 (8_Supplement): 133.

Published: 15 April 2006

View article titled, In vitro and in vivo effects of the combination of SR57746A (Xaliproden), a neuroprotective agent, with oxaliplatin (ELOXATIN®) in colon tumors

Journal Articles

Pre-clinical evaluation of the anti-tumor activity of the IGF1R - specific anitbody AVE1642

Friedhelm Bladt, Patricia Vrignaud, Marielle Chiron, Corinne Venot, Laurent Debussche, Rajeeva Singh, Thomas Chittenden, Thierry Hercend, Marie-Christine Bissery

Cancer Res (2006) 66 (8_Supplement): 289–290.

Published: 15 April 2006

View article titled, Pre-clinical evaluation of the anti-tumor activity of the IGF1R - specific anitbody AVE1642

Journal Articles

The tumor vascular-targeting agent AVE8062 induces tumor blood flow shut down and necrosis in an orthotopic model of colon cancer in mice

Magali Guffroy, Claire Dally, Patricia Vrignaud, Eric Beys, Marie-Christine Bissery

Cancer Res (2005) 65 (9_Supplement): 804.

Published: 01 May 2005

View article titled, The tumor vascular-targeting agent AVE8062 induces tumor blood flow shut down and necrosis in an orthotopic model of colon cancer in mice

Journal Articles

In vivo synergy between doxorubicin, cisplatin or vinorelbine and RPR 109881A, a new taxoid

Patricia Vrignaud, Pascale Lejeune, Marie-Christine Bissery

Cancer Res (2005) 65 (9_Supplement): 805.

Published: 01 May 2005

View article titled, In vivo synergy between doxorubicin, cisplatin or vinorelbine and RPR 109881A, a new taxoid

Journal Articles

In vivo synergy between docetaxel and AVE8062A, a tumor vasculature targeting agent

Pascale Lejeune, Patricia Vrignaud, Hélène Goulaouic, Sylvain Nicolas, Marie-Christine Bissery

Cancer Res (2005) 65 (9_Supplement): 807–808.

Published: 01 May 2005

View article titled, In vivo synergy between docetaxel and AVE8062A, a tumor vasculature targeting agent

Journal Articles

In vivo evaluation of the antiangiogenic agent VEGF Trap, alone and in combination with 5-fluorouracil

Marielle Chiron, Patricia Vrignaud, Pascale Lejeune, Joyce Muller, Thierry Hercend, Marie-Christine Bissery

Cancer Res (2005) 65 (9_Supplement): 129.

Published: 01 May 2005

View article titled, In vivo evaluation of the antiangiogenic agent VEGF Trap, alone and in combination with 5-fluorouracil

Journal Articles

Preclinical evaluation of XRP9881A, a new taxoid

Marie-Christine Bissery, Patricia Vrignaud, Cécile Combeau, Jean-François Riou, Hervé Bouchard, Alain Commerçon, François Lavelle

Cancer Res (2004) 64 (7_Supplement): 1253.

Published: 01 April 2004

View article titled, Preclinical evaluation of XRP9881A, a new taxoid

NARROW

Abstract 2507: Bivalent adenylate cyclase (CYA)-based therapeutic vaccines: eradication of tumor cells expressing different antigens over time

Abstract 714: Non-invasive monitoring of the antitumor activity of SAR650984 anti-CD38 antibody against disseminated human Daudi lymphoma using ¹⁸F-FDG micro Positron Emission Tomography

Abstract #2797: In vivo therapeutic synergy of SAR650984, a humanized anti-CD38 antibody, in combination with melphalan in a multiple myeloma xenograft.

Abstract #859: Broad spectrum of antitumor activity of SAR650984, a humanized anti-CD38 antibody targeting hematological malignancies

Broad spectrum of antitumor activity of aflibercept (VEGF Trap) in tumor-bearing mice.

Combination of the antiangiogenic agent aflibercept (VEGF Trap) with docetaxel or gemcitabine results in greater antitumor activity in tumor bearing mice.

Antitumor activity of alvocidib (flavopiridol) in mice bearing human hematological tumors

Characterization of vascular-disrupting properties of the Combretastatin A4 derivative AVE8062 in the rat aortic ring assay

Demonstration in animal and human of AVE8062-induced tumor blood flow shutdown using dynamic contrast enhanced-ultrasonography (DCE-US).

In vivo pre-clinical evaluation of the IGF-1R-specific antibody AVE1642 as single agent and in combination with Velcade ^® /Bortezomib

In vivo synergy between trastuzumab (herceptin ^® ) and larotaxel (RPR 109881A), a new taxoid.

Early evaluation of the antimitotic and vascular targeting agent AVE8062A in melanoma tumor bearing mice using dynamic contrast enhanced-ultrasonography (DCE-US)

Preclinical evaluation of SAR3419 (huB4-DM4), an anti-CD19-maytansinoid immunoconjugate, for the treatment of B cell lymphomas

In vitro and in vivo effects of the combination of SR57746A (Xaliproden), a neuroprotective agent, with oxaliplatin (ELOXATIN®) in colon tumors

Pre-clinical evaluation of the anti-tumor activity of the IGF1R - specific anitbody AVE1642

The tumor vascular-targeting agent AVE8062 induces tumor blood flow shut down and necrosis in an orthotopic model of colon cancer in mice

In vivo synergy between doxorubicin, cisplatin or vinorelbine and RPR 109881A, a new taxoid

In vivo synergy between docetaxel and AVE8062A, a tumor vasculature targeting agent

In vivo evaluation of the antiangiogenic agent VEGF Trap, alone and in combination with 5-fluorouracil

Preclinical evaluation of XRP9881A, a new taxoid

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only